Quality of oral anticoagulation control in Chinese patients with non-valvular atrial fibrillation: a prospective controlled study.

Objective: The sex, age, medical history, treatment, tobacco use, race risk (SAMe-TTR) Score; the sex, age, medical history, treatment, tobacco use, genotype combination (SAMe-TTG) Score; and the so-called modified SAMe-TTR scores have been proposed to predict the anticoagulation quality for patients with non-valvular atrial fibrillation (NVAF). The data from a prospective controlled study is used to validate the SAMe-TTR and SAMe-TTG scores in Chinese NVAF patients treated with warfarin and to evaluate the association of factors with time in therapeutic range (TTR) to predict the quality of oral anticoagulation control.

Methods: A total of 379 patients with NVAF under warfarin treatment for a three-month follow-up were included in this prospective, multicenter study.

Genotype-Guided Dosing of Warfarin in Chinese Adults: A Multicenter Randomized Clinical Trial.

Background: Warfarin is an effective treatment for thromboembolic disease but has a narrow therapeutic index; optimal anticoagulation dosage can differ tremendously among individuals. We aimed to evaluate whether genotype-guided warfarin dosing is superior to routine clinical dosing for the outcomes of interest in Chinese patients.

Methods: We conducted a multicenter, randomized, single-blind, parallel-controlled trial from September 2014 to April 2017 in 15 hospitals in China.